{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:04:35Z","timestamp":1761487475251},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1038\/sj.bjc.6602814","type":"journal-article","created":{"date-parts":[[2005,10,19]],"date-time":"2005-10-19T11:49:59Z","timestamp":1129722599000},"page":"979-985","source":"Crossref","is-referenced-by-count":29,"title":["Effects of platinum\/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI"],"prefix":"10.1038","volume":"93","author":[{"given":"K J","family":"Lankester","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N J","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J J","family":"Stirling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Boxall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"D'Arcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M O","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J S","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A R","family":"Padhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,10,18]]},"reference":[{"key":"BF6602814_CR1","unstructured":"Ah-See M-LW, Makris A, Taylor NJ, Harrison M, Richman PI, D'Arcy JA, Burcombe RJ, Pittam MR, Ravichandran D, Stirling JJ, Leach MO, Padhani AR (2004) T1 and T2* weighted dynamic contrast-enhanced MRI predicts for clinico-pathological response to neoadjuvant chemotherapy in primary breast cancer. Proc ISMRM, Vol 12, 1992, Kyoto, Japan"},{"key":"BF6602814_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/0277-5379(91)90391-P","volume":"27","author":"BC Baguley","year":"1991","unstructured":"Baguley BC, Holdaway KH, Thomsen LL, Zhuang L, Zwi L (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27: 482\u2013487","journal-title":"Eur J Cancer"},{"key":"BF6602814_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1148\/radiology.207.3.9609906","volume":"207","author":"JO Barentsz","year":"1998","unstructured":"Barentsz JO, Berger-Hartog O, Witjes JA, Hulsbergen-van der Kaa C, Oosterhof GO, VanderLaak JA, Kondacki H, Ruijs SH (1998) Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 207: 791\u2013797","journal-title":"Radiology"},{"key":"BF6602814_CR4","first-page":"1843","volume":"2","author":"D Belotti","year":"1996","unstructured":"Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli M, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843\u20131849","journal-title":"Clin Cancer Res"},{"key":"BF6602814_CR5","unstructured":"Beresford MJ, Ah-See M-LW, Taylor NJ, Stirling JJ, Makris A, D'Arcy JA, Leach MO, Padhani AR (2005) Inter- and intra-observer variability of DCE-MRI in breast cancer. Proc ISMRM, Miami Beach, FL, Vol 13, pp 1863"},{"key":"BF6602814_CR6","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/bmj.313.7059.744","volume":"313","author":"J Bland","year":"1996","unstructured":"Bland J, Altman D (1996a) Measurement error [corrected and republished article originally printed in BMJ 1996 Jun 29; 312(7047):1654] [see comments]. BMJ 313: 744","journal-title":"BMJ"},{"key":"BF6602814_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/bmj.313.7049.106","volume":"313","author":"J Bland","year":"1996","unstructured":"Bland J, Altman D (1996b) Measurement error proportional to the mean [published erratum appears in BMJ 1996 Sep 21; 313(7059):744]. BMJ 313: 106","journal-title":"BMJ"},{"key":"BF6602814_CR8","first-page":"4206","volume":"48","author":"P Braunschweiger","year":"1988","unstructured":"Braunschweiger P (1988) Effect of cyclophosphamide on the pathophysiology of RIF-1 solid tumors. Cancer Res 48: 4206\u20134210","journal-title":"Cancer Res"},{"key":"BF6602814_CR9","first-page":"1878","volume":"60","author":"T Browder","year":"2000","unstructured":"Browder T, Butterfield C, Kraling B, Shi B, Marshall B, O'Reilly M, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878\u20131886","journal-title":"Cancer Res"},{"key":"BF6602814_CR10","volume-title":"Textbook of Medical Oncology","author":"F Cavalli","year":"2000","unstructured":"Cavalli F, Hansen HH, Kaye SB (2000) Textbook of Medical Oncology. London: Martin Dunitz Ltd"},{"key":"BF6602814_CR11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0360-3016(02)03924-X","volume":"54","author":"D Chaplin","year":"2002","unstructured":"Chaplin D, Hill S (2002) The development of Combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 54: 1491\u20131496","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BF6602814_CR12","first-page":"S86","volume":"27","author":"DJ Chaplin","year":"1996","unstructured":"Chaplin DJ, Pettit GR, Parkins CS, Hill SA (1996) Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 27: S86\u2013S88","journal-title":"Br J Cancer Suppl"},{"key":"BF6602814_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/sj.bjc.6601386","volume":"89","author":"D Checkley","year":"2003","unstructured":"Checkley D, Tessier JJ, Kendrew J, Waterton JC, Wedge SR (2003a) Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 89: 1889\u20131895","journal-title":"Br J Cancer"},{"key":"BF6602814_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0730-725X(02)00644-6","volume":"21","author":"D Checkley","year":"2003","unstructured":"Checkley D, Tessier JJ, Wedge SR, Dukes M, Kendrew J, Curry B, Middleton B, Waterton JC (2003b) Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magn Reson Imaging 21: 475\u2013482","journal-title":"Magn Reson Imaging"},{"key":"BF6602814_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/annonc\/mdf013","volume":"13","author":"M Colleoni","year":"2002","unstructured":"Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13: 73\u201380","journal-title":"Ann Oncol"},{"key":"BF6602814_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1109\/MEMB.2004.1360410","volume":"23","author":"DJ Collins","year":"2004","unstructured":"Collins DJ, Padhani AR (2004) Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges. IEEE Engl Med Biol Mag 23: 65\u201383","journal-title":"IEEE Engl Med Biol Mag"},{"key":"BF6602814_CR17","first-page":"1829","volume":"57","author":"GG Dark","year":"1997","unstructured":"Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumour vasculature. Cancer Res 57: 1829\u20131834","journal-title":"Cancer Res"},{"key":"BF6602814_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/mrm.1910320110","volume":"32","author":"K Donahue","year":"1994","unstructured":"Donahue K, Burstein D, Manning W, Gray M (1994) Studies of Gd-DTPA relaxivity and proton exchange rates in tissue. Magn Reson Med 32: 66\u201376","journal-title":"Magn Reson Med"},{"key":"BF6602814_CR19","first-page":"3408","volume":"62","author":"A Dowlati","year":"2002","unstructured":"Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae KR, Remick SC (2002) A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 62: 3408\u20133416","journal-title":"Cancer Res"},{"key":"BF6602814_CR20","unstructured":"Evelhoch J, LoRusso P, DelProposto Z, Stark K, Latif Z, Morton P, Waterton J, Wheeler C, Barge A (2002) Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature in a phase I clinical trial. Proc ISMRM, Honolulu, Hawaii, Vol 10, 2095pp"},{"key":"BF6602814_CR21","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-03-0417","volume":"10","author":"JL Evelhoch","year":"2004","unstructured":"Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC, Waterton JC (2004) Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 10: 3650\u20133657","journal-title":"Clin Cancer Res"},{"key":"BF6602814_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/nbm.731","volume":"15","author":"S Galbraith","year":"2002","unstructured":"Galbraith S, Lodge M, Taylor N, Rustin G, Bentzen S, Stirling J, Padhani A (2002a) Reproducibility of dynamic contrast enhanced MRI in human muscle and tumours \u2013 comparison of quantitative and semi-quantitative analysis. NMR Biomed 15: 132\u2013142","journal-title":"NMR Biomed"},{"key":"BF6602814_CR23","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1200\/JCO.2003.05.187","volume":"21","author":"SM Galbraith","year":"2003","unstructured":"Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJS (2003) Combretastatin A4 phosphate has tumour anti-vascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 21: 2831\u20132842","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR24","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1200\/JCO.2002.09.144","volume":"20","author":"SM Galbraith","year":"2002","unstructured":"Galbraith SM, Rustin GJS, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, Thompson P, Hough D, Gumbrell L, Padhani AR (2002b) Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 20: 3826\u20133840","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jmri.10072","volume":"15","author":"A Gossmann","year":"2002","unstructured":"Gossmann A, Helbich TH, Kuriyama N, Ostrowitzki S, Roberts TP, Shames DM, van Bruggen N, Wendland MF, Israel MA, Brasch RC (2002) Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 15: 233\u2013240","journal-title":"J Magn Reson Imaging"},{"key":"BF6602814_CR26","first-page":"3776","volume":"59","author":"G Griffon-Etienne","year":"1999","unstructured":"Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 59: 3776\u20133782","journal-title":"Cancer Res"},{"key":"BF6602814_CR27","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/0959-8049(93)90082-Q","volume":"29A","author":"SA Hill","year":"1993","unstructured":"Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 29A: 1320\u20131324","journal-title":"Eur J Cancer"},{"key":"BF6602814_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/ijc.2910630121","volume":"63","author":"SA Hill","year":"1995","unstructured":"Hill SA, Sampson LE, Chaplin DJ (1995) Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119\u2013123","journal-title":"Int J Cancer"},{"key":"BF6602814_CR29","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/jnci\/94.19.1484","volume":"94","author":"GC Jayson","year":"2002","unstructured":"Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings D, Lawrance J, Haroon H, Ward T, McGown AT, Tang M, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94: 1484\u20131493","journal-title":"J Natl Cancer Inst"},{"key":"BF6602814_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/(SICI)1098-1128(199807)18:4<259::AID-MED3>3.0.CO;2-U","volume":"18","author":"A Jordan","year":"1998","unstructured":"Jordan A, Hadfield JA, Lawrence NJ, McGown AT (1998) Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 18: 259\u2013296","journal-title":"Med Res Rev"},{"key":"BF6602814_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/annonc\/mdf093","volume":"13","author":"RS Kerbel","year":"2002","unstructured":"Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose anti-angiogenic\/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13: 12\u201315","journal-title":"Ann Oncol"},{"key":"BF6602814_CR32","first-page":"223","volume":"8","author":"S Kety","year":"1960","unstructured":"Kety S (1960) Blood-tissue exchange methods. Theory of blood\u2013tissue exchange and its application to measurement of blood flow. Methods Med Res 8: 223\u2013227","journal-title":"Methods Med Res"},{"key":"BF6602814_CR33","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/sj.bjc.6602550","volume":"92","author":"MO Leach","year":"2005","unstructured":"Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A, Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR, Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W, Waterton JC, Williams SR, Workman P (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92: 1599\u20131610","journal-title":"Br J Cancer"},{"key":"BF6602814_CR34","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mrm.1910220106","volume":"22","author":"S Li","year":"1991","unstructured":"Li S, Wehrle J, Glickson J, Kumar N, Braunschweiger P (1991) Tumor bioenergetics and blood flow in RIF-1 murine tumors treated with 5-fluorouracil. Magn Reson Med 22: 47\u201356","journal-title":"Magn Reson Med"},{"key":"BF6602814_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/nbm.754","volume":"15","author":"R Maxwell","year":"2002","unstructured":"Maxwell R, Wilson J, Prise V, Vojnovic B, Rustin G, Lodge M, Tozer G (2002) Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 15: 89\u201398","journal-title":"NMR Biomed"},{"key":"BF6602814_CR36","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1200\/JCO.2001.19.4.1195","volume":"19","author":"KD Miller","year":"2001","unstructured":"Miller KD, Sweeney CJ, Sledge Jr GW (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195\u20131206","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR37","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1200\/JCO.2003.08.092","volume":"21","author":"B Morgan","year":"2003","unstructured":"Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787\/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955\u20133964","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/00002142-200402000-00005","volume":"15","author":"AR Padhani","year":"2004","unstructured":"Padhani AR, Dzik-Jurasz A (2004) Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging 15: 41\u201357","journal-title":"Top Magn Reson Imaging"},{"key":"BF6602814_CR39","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/nbm.732","volume":"15","author":"AR Padhani","year":"2002","unstructured":"Padhani AR, Hayes C, Landau S, Leach MO (2002) Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 15: 143\u2013153","journal-title":"NMR Biomed"},{"key":"BF6602814_CR40","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1148\/radiographics.18.2.9536492","volume":"18","author":"G Parker","year":"1998","unstructured":"Parker G, Suckling J, Tanner S, Padhani A, Husband J, Leach M (1998) MRIW: parametric analysis software for contrast-enhanced dynamic MR imaging in cancer. Radiographics 18: 497\u2013506","journal-title":"Radiographics"},{"key":"BF6602814_CR41","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/jmri.1880070318","volume":"7","author":"GJ Parker","year":"1997","unstructured":"Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, Leach MO (1997) Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics. J Magn Reson Imaging 7: 564\u2013574","journal-title":"J Magn Reson Imaging"},{"key":"BF6602814_CR42","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<277::AID-JMRI8>3.0.CO;2-S","volume":"10","author":"W Reddick","year":"1999","unstructured":"Reddick W, Taylor J, Fletcher B (1999) Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging 10: 277\u2013285","journal-title":"J Magn Reson Imaging"},{"key":"BF6602814_CR43","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.2003.01.223","volume":"21","author":"GJ Rustin","year":"2003","unstructured":"Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21: 187\u2013193","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR44","first-page":"4266","volume":"61","author":"G Sersa","year":"2001","unstructured":"Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Cemazar M, Auersperg M, Swartz HM (2001) Reduced tumor oxygenation by treatment with vinblastine. Cancer Res 61: 4266\u20134271","journal-title":"Cancer Res"},{"key":"BF6602814_CR45","doi-asserted-by":"publisher","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","volume":"21","author":"JP Stevenson","year":"2003","unstructured":"Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O'Dwyer PJ (2003) Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 21: 4428\u20134438","journal-title":"J Clin Oncol"},{"key":"BF6602814_CR46","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"BF6602814_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","volume":"10","author":"PE Thorpe","year":"2004","unstructured":"Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415\u2013427","journal-title":"Clin Cancer Res"},{"key":"BF6602814_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jmri.1880070113","volume":"7","author":"PS Tofts","year":"1997","unstructured":"Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7: 91\u2013101","journal-title":"J Magn Reson Imaging"},{"key":"BF6602814_CR49","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","volume":"10","author":"P Tofts","year":"1999","unstructured":"Tofts P, Brix G, Buckley D, Evelhoch J, Henderson E, Knopp M, Larsson H, Lee T, Mayr N, Parker G, Port R, Taylor J, Weisskoff R (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10: 223\u2013232","journal-title":"J Magn Reson Imaging"},{"key":"BF6602814_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/mrm.1910170208","volume":"17","author":"PS Tofts","year":"1991","unstructured":"Tofts PS, Kermode AG (1991) Measurement of the blood\u2013brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17: 357\u2013367","journal-title":"Magn Reson Med"},{"key":"BF6602814_CR51","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-2613.2002.00211.x","volume":"83","author":"GM Tozer","year":"2002","unstructured":"Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83: 21\u201338","journal-title":"Int J Exp Pathol"},{"key":"BF6602814_CR52","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1002\/1097-0142(20000601)88:11<2619::AID-CNCR26>3.0.CO;2-J","volume":"88","author":"TH Wang","year":"2000","unstructured":"Wang TH, Wang HS, Soong YK (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88: 2619\u20132628","journal-title":"Cancer"},{"key":"BF6602814_CR53","first-page":"167","volume":"16","author":"HJ Weinmann","year":"1984","unstructured":"Weinmann HJ, Laniado M, Mutzel W (1984) Pharmacokinetics of GdDTPA\/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 16: 167\u2013172","journal-title":"Physiol Chem Phys Med NMR"},{"key":"BF6602814_CR54","unstructured":"Wolf W, Presant C, Waluch V, Leberthon B (2003) A unique methodology using dynamic contrast enhanced MRI (DEMRI) for quantifying anti-angiogenic effects (AAE) of chemotherapy: AAE of docetaxel (DOC) correlate with tumor response (TR). Proc ASCO, Chicago, 824pp"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6602814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602814","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6602814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:18:24Z","timestamp":1684412304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6602814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["BF6602814"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6602814","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}